Ikeda Fumiaki
Department of Infectious Diseases, Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co. Ltd., Osaka, Japan.
Nihon Yakurigaku Zasshi. 2003 Oct;122(4):339-44. doi: 10.1254/fpj.122.339.
Micafungin sodium (MCFG) is a new lipopeptide antifungal agent of the echinocandin class. MCFG inhibits 1,3-beta-glucan synthesis in C. albicans and A. fumigatus in a non-competitive manner and has antifungal activity against both Aspergillus and Candida species. In neutropenic mouse models of disseminated candidiasis and pulmonary aspergillosis, the efficacy of MCFG was superior to that of fluconazole and itroconazole, but comparable to that of amphotericin B. The efficacy and safety of MCFG were investigated in 70 patients with deep-seated mycosis caused by Candida and Aspergillus species. The overall clinical response rates were 57.1% in aspergillosis and 78.6% in candidiasis. The incidence of adverse events related to micafungin was 17.9 %, and there was no dose-related occurrence of any adverse events. The results from this study indicated that micafungin was effective against aspergillosis and candidiasis, with no tolerability problems.
米卡芬净钠（MCFG）是一种新型的棘白菌素类脂肽抗真菌药物。MCFG以非竞争性方式抑制白色念珠菌和烟曲霉中1,3-β-葡聚糖的合成，对曲霉属和念珠菌属均具有抗真菌活性。在播散性念珠菌病和肺曲霉病的中性粒细胞减少小鼠模型中，MCFG的疗效优于氟康唑和伊曲康唑，但与两性霉素B相当。对70例由念珠菌属和曲霉属引起的深部真菌病患者进行了MCFG疗效和安全性的研究。曲霉病的总体临床有效率为57.1%，念珠菌病为78.6%。与米卡芬净相关的不良事件发生率为17.9%，且未出现任何与剂量相关的不良事件。本研究结果表明，米卡芬净对曲霉病和念珠菌病有效，且无耐受性问题。
